Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 36

1.

SB265610 is an allosteric, inverse agonist at the human CXCR2 receptor.

Bradley ME, Bond ME, Manini J, Brown Z, Charlton SJ.

Br J Pharmacol. 2009 Sep;158(1):328-38. doi: 10.1111/j.1476-5381.2009.00182.x. Epub 2009 Apr 24. Erratum in: Br J Pharmacol. 2009 Oct;158(3):931.

2.

Nonpeptidergic allosteric antagonists differentially bind to the CXCR2 chemokine receptor.

de Kruijf P, van Heteren J, Lim HD, Conti PG, van der Lee MM, Bosch L, Ho KK, Auld D, Ohlmeyer M, Smit MJ, Wijkmans JC, Zaman GJ, Smit MJ, Leurs R.

J Pharmacol Exp Ther. 2009 May;329(2):783-90. doi: 10.1124/jpet.108.148387. Epub 2009 Feb 3. Erratum in: J Pharmacol Exp Ther. 2009 Jul;330(1):367.

3.

CXCR2 antagonists for the treatment of pulmonary disease.

Chapman RW, Phillips JE, Hipkin RW, Curran AK, Lundell D, Fine JS.

Pharmacol Ther. 2009 Jan;121(1):55-68. doi: 10.1016/j.pharmthera.2008.10.005. Epub 2008 Oct 31. Review.

PMID:
19026683
4.

Identification of a putative intracellular allosteric antagonist binding-site in the CXC chemokine receptors 1 and 2.

Nicholls DJ, Tomkinson NP, Wiley KE, Brammall A, Bowers L, Grahames C, Gaw A, Meghani P, Shelton P, Wright TJ, Mallinder PR.

Mol Pharmacol. 2008 Nov;74(5):1193-202. doi: 10.1124/mol.107.044610. Epub 2008 Aug 1.

5.

Neutrophil isolation from nonhuman species.

Siemsen DW, Schepetkin IA, Kirpotina LN, Lei B, Quinn MT.

Methods Mol Biol. 2007;412:21-34. doi: 10.1007/978-1-59745-467-4_3.

PMID:
18453103
6.

Evaluation of a series of bicyclic CXCR2 antagonists.

Walters I, Austin C, Austin R, Bonnert R, Cage P, Christie M, Ebden M, Gardiner S, Grahames C, Hill S, Hunt F, Jewell R, Lewis S, Martin I, David Nicholls, David Robinson.

Bioorg Med Chem Lett. 2008 Jan 15;18(2):798-803.

PMID:
18240390
7.

Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2.

Moriconi A, Cesta MC, Cervellera MN, Aramini A, Coniglio S, Colagioia S, Beccari AR, Bizzarri C, Cavicchia MR, Locati M, Galliera E, Di Benedetto P, Vigilante P, Bertini R, Allegretti M.

J Med Chem. 2007 Aug 23;50(17):3984-4002. Epub 2007 Aug 1.

PMID:
17665889
8.

Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist.

Gonsiorek W, Fan X, Hesk D, Fossetta J, Qiu H, Jakway J, Billah M, Dwyer M, Chao J, Deno G, Taveras A, Lundell DJ, Hipkin RW.

J Pharmacol Exp Ther. 2007 Aug;322(2):477-85. Epub 2007 May 11.

9.

Chemokine: receptor structure, interactions, and antagonism.

Allen SJ, Crown SE, Handel TM.

Annu Rev Immunol. 2007;25:787-820. Review.

PMID:
17291188
10.

Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist.

Dwyer MP, Yu Y, Chao J, Aki C, Chao J, Biju P, Girijavallabhan V, Rindgen D, Bond R, Mayer-Ezel R, Jakway J, Hipkin RW, Fossetta J, Gonsiorek W, Bian H, Fan X, Terminelli C, Fine J, Lundell D, Merritt JR, Rokosz LL, Kaiser B, Li G, Wang W, Stauffer T, Ozgur L, Baldwin J, Taveras AG.

J Med Chem. 2006 Dec 28;49(26):7603-6.

PMID:
17181143
11.

ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets.

Bizzarri C, Beccari AR, Bertini R, Cavicchia MR, Giorgini S, Allegretti M.

Pharmacol Ther. 2006 Oct;112(1):139-49. Epub 2006 May 23. Review.

PMID:
16720046
12.

Synthesis and structure-activity relationships of 3,4-diaminocyclobut-3-ene-1,2-dione CXCR2 antagonists.

Merritt JR, Rokosz LL, Nelson KH Jr, Kaiser B, Wang W, Stauffer TM, Ozgur LE, Schilling A, Li G, Baldwin JJ, Taveras AG, Dwyer MP, Chao J.

Bioorg Med Chem Lett. 2006 Aug 1;16(15):4107-10. Epub 2006 May 11.

PMID:
16697193
13.

Development of a systemically-active dual CXCR1/CXCR2 allosteric inhibitor and its efficacy in a model of transient cerebral ischemia in the rat.

Garau A, Bertini R, Mosca M, Bizzarri C, Anacardio R, Triulzi S, Allegretti M, Ghezzi P, Villa P.

Eur Cytokine Netw. 2006 Mar;17(1):35-41.

14.

Imidazolylpyrimidine based CXCR2 chemokine receptor antagonists.

Ho KK, Auld DS, Bohnstedt AC, Conti P, Dokter W, Erickson S, Feng D, Inglese J, Kingsbury C, Kultgen SG, Liu RQ, Masterson CM, Ohlmeyer M, Rong Y, Rooseboom M, Roughton A, Samama P, Smit MJ, Son E, van der Louw J, Vogel G, Webb M, Wijkmans J, You M.

Bioorg Med Chem Lett. 2006 May 15;16(10):2724-8. Epub 2006 Mar 15.

PMID:
16540318
15.

A novel mechanism of neutrophil recruitment in a coculture model of the rheumatoid synovium.

Lally F, Smith E, Filer A, Stone MA, Shaw JS, Nash GB, Buckley CD, Rainger GE.

Arthritis Rheum. 2005 Nov;52(11):3460-9.

16.

2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors.

Allegretti M, Bertini R, Cesta MC, Bizzarri C, Di Bitondo R, Di Cioccio V, Galliera E, Berdini V, Topai A, Zampella G, Russo V, Di Bello N, Nano G, Nicolini L, Locati M, Fantucci P, Florio S, Colotta F.

J Med Chem. 2005 Jun 30;48(13):4312-31.

PMID:
15974585
17.

Different ELR (+) angiogenic CXC chemokine profiles in synovial fluid of patients with Behçet's disease, familial Mediterranean fever, rheumatoid arthritis, and osteoarthritis.

Erdem H, Pay S, Serdar M, Simşek I, Dinç A, Muşabak U, Pekel A, Turan M.

Rheumatol Int. 2005 Dec;26(2):162-7. Epub 2004 Nov 3.

PMID:
15672235
18.

Inhibition of interleukin-8 (CXCL8/IL-8) responses by repertaxin, a new inhibitor of the chemokine receptors CXCR1 and CXCR2.

Casilli F, Bianchini A, Gloaguen I, Biordi L, Alesse E, Festuccia C, Cavalieri B, Strippoli R, Cervellera MN, Di Bitondo R, Ferretti E, Mainiero F, Bizzarri C, Colotta F, Bertini R.

Biochem Pharmacol. 2005 Feb 1;69(3):385-94. Epub 2004 Dec 9.

PMID:
15652230
19.

Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury.

Bertini R, Allegretti M, Bizzarri C, Moriconi A, Locati M, Zampella G, Cervellera MN, Di Cioccio V, Cesta MC, Galliera E, Martinez FO, Di Bitondo R, Troiani G, Sabbatini V, D'Anniballe G, Anacardio R, Cutrin JC, Cavalieri B, Mainiero F, Strippoli R, Villa P, Di Girolamo M, Martin F, Gentile M, Santoni A, Corda D, Poli G, Mantovani A, Ghezzi P, Colotta F.

Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11791-6. Epub 2004 Jul 28.

20.

Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist.

Beaumont K, Webster R, Gardner I, Dack K.

Curr Drug Metab. 2003 Dec;4(6):461-85. Review.

PMID:
14683475

Supplemental Content

Support Center